Literature DB >> 24179618

Risk factors for liver fibrosis among human immunodeficiency virus monoinfected patients using the FIB4 index in Morocco.

Mohamed Tahiri1, Mustapha Sodqi, Fatima Ez Zahra Lahdami, Latifa Marih, Hassan Lamdini, Wafaa Hliwa, Ahd Oulad Lahcen, Wafaa Badre, Fouad Haddad, Abdelfetah Chakib, Ahmed Bellabah, Rhimou Alaoui, Kamal Marhoum El Filali.   

Abstract

AIM: To study the prevalence and risk factors of significant hepatic fibrosis in Moroccan human immunodeficiency virus (HIV) monoinfected patients.
METHODS: We conducted a cross-sectional study among HIV monoinfected patients (negative for hepatitis B surface antigen and hepatitis C antibody). Clinical and laboratory data were collected from the data base of the Infectious Diseases Unit in Ibn Rochd Hospital Center [age, gender, duration of HIV infection, CD4 T lymphocyte count, HIV viral load, glycemia and current or prior use of antiretroviral and antiretroviral therapy (ART) duration]. The primary outcome was a FIB4 score > 1.45. Multivariable logistic regression identified independent risk factors for FIB4 > 1.45.
RESULTS: A FIB4 score > 1.45 was identified in 96 among 619 (15.5%). HIV monoinfected patients followed up between September 1990 and September 2012. Multivariate analysis showed that only a viral load > 75 (OR = 2.23, 95%CI: 1.36-3.67), CD4 > 200 cells/mm(3) (OR = 0.39, 95%CI: 0.21-0.72) and age at FIB4 index calculation (OR = 1.10, 95%CI: 1.07-1.13) were independently associated with the occurrence of FIB4 index (> 1.45). Gender, duration of HIV infection, glycemia, use of antiretroviral therapy and ART duration were not associated with significant fibrosis by FIB4.
CONCLUSION: FIB4 score > 1.45 was found in 15.5% of Moroccan HIV monoinfected patients. Age, HIV viremia > 75 copies/mL and CD4 count > 200 cells/mm(3) are associated with liver fibrosis. Further studies are needed to explore mechanisms for fibrosis in HIV monoinfected patients.

Entities:  

Keywords:  FIB4; Human immunodeficiency virus; Liver; Monoinfected; Risk factors

Year:  2013        PMID: 24179618      PMCID: PMC3812461          DOI: 10.4254/wjh.v5.i10.584

Source DB:  PubMed          Journal:  World J Hepatol


  32 in total

1.  Trends in diseases reported on U.S. death certificates that mentioned HIV infection, 1987-1999.

Authors:  Richard M Selik; Robert H Byers; Mark S Dworkin
Journal:  J Acquir Immune Defic Syndr       Date:  2002-04-01       Impact factor: 3.731

2.  Factors associated with specific causes of death amongst HIV-positive individuals in the D:A:D Study.

Authors:  Colette Smith; Caroline A Sabin; Jens D Lundgren; Rodolphe Thiebaut; Rainer Weber; Matthew Law; Antonella d'Arminio Monforte; Ole Kirk; Nina Friis-Moller; Andrew Phillips; Peter Reiss; Wafaa El Sadr; Christian Pradier; Signe W Worm
Journal:  AIDS       Date:  2010-06-19       Impact factor: 4.177

3.  Cancer in cohort of HIV-infected population: prevalence and clinical characteristics.

Authors:  Yong-xi Zhang; Xi-en Gui; Ya-hua Zhong; Yu-ping Rong; Ya-jun Yan
Journal:  J Cancer Res Clin Oncol       Date:  2010-06-08       Impact factor: 4.553

4.  Low frequency of liver enzyme elevation in HIV-infected patients attending a large urban treatment centre in Uganda.

Authors:  P Ocama; B Castelnuovo; M R Kamya; G D Kirk; S J Reynolds; A Kiragga; R Colebunders; D L Thomas
Journal:  Int J STD AIDS       Date:  2010-08       Impact factor: 1.359

5.  Human immunodeficiency virus (HIV)-1 infects human hepatic stellate cells and promotes collagen I and monocyte chemoattractant protein-1 expression: implications for the pathogenesis of HIV/hepatitis C virus-induced liver fibrosis.

Authors:  Ana C Tuyama; Feng Hong; Yedidya Saiman; Chuansheng Wang; Derya Ozkok; Arevik Mosoian; Ping Chen; Benjamin K Chen; Mary E Klotman; Meena B Bansal
Journal:  Hepatology       Date:  2010-08       Impact factor: 17.425

6.  Liver-related deaths in persons infected with the human immunodeficiency virus: the D:A:D study.

Authors:  Rainer Weber; Caroline A Sabin; Nina Friis-Møller; Peter Reiss; Wafaa M El-Sadr; Ole Kirk; Francois Dabis; Matthew G Law; Christian Pradier; Stephane De Wit; Börje Akerlund; Gonzalo Calvo; Antonella d'Arminio Monforte; Martin Rickenbach; Bruno Ledergerber; Andrew N Phillips; Jens D Lundgren
Journal:  Arch Intern Med       Date:  2006 Aug 14-28

7.  Evaluation of liver fibrosis: concordance analysis between noninvasive scores (APRI and FIB-4) evolution and predictors in a cohort of HIV-infected patients without hepatitis C and B infection.

Authors:  Monia Mendeni; Emanuele Focà; Daria Gotti; Nicoletta Ladisa; Gioacchino Angarano; Laura Albini; Filippo Castelnuovo; Giampiero Carosi; Eugenia Quiros-Roldan; Carlo Torti
Journal:  Clin Infect Dis       Date:  2011-05       Impact factor: 9.079

8.  HIV mono-infection is associated with FIB-4 - A noninvasive index of liver fibrosis - in women.

Authors:  Jason T Blackard; Jeffrey A Welge; Lynn E Taylor; Kenneth H Mayer; Robert S Klein; David D Celentano; Denise J Jamieson; Lytt Gardner; Kenneth E Sherman
Journal:  Clin Infect Dis       Date:  2011-01-19       Impact factor: 9.079

Review 9.  Platelets and HIV-1 infection: old and new aspects.

Authors:  Donato Torre; Agostino Pugliese
Journal:  Curr HIV Res       Date:  2008-09       Impact factor: 1.581

10.  Increasing incidence of critical liver disease among causes of death in Japanese hemophiliacs with HIV-1.

Authors:  Shinobu Tatsunami; Masashi Taki; Akira Shirahata; Junichi Mimaya; Kaneo Yamada
Journal:  Acta Haematol       Date:  2004       Impact factor: 2.195

View more
  8 in total

1.  HIV-1 infected peripheral blood mononuclear cells modulate the fibrogenic activity of hepatic stellate cells through secreted TGF-β and JNK signaling.

Authors:  Deepti Gupta; Manjusha Rani; Nabab Khan; Shahid Jameel
Journal:  PLoS One       Date:  2014-03-17       Impact factor: 3.240

2.  The Impact of Human Pegivirus on CD4 Cell Count in HIV-Positive Persons in Botswana.

Authors:  Kombo F N'Guessan; Motswedi Anderson; Bonolo Phinius; Sikhulile Moyo; Alyyah Malick; Tshepiso Mbangiwa; Wonderful T Choga; Joseph Makhema; Richard Marlink; Max Essex; Rosemary Musonda; Simani Gaseitsiwe; Jason T Blackard
Journal:  Open Forum Infect Dis       Date:  2017-10-10       Impact factor: 3.835

3.  High Rates of Occult Hepatitis B Virus Infection in HIV-Positive Individuals Initiating Antiretroviral Therapy in Botswana.

Authors:  Kathleen Ryan; Motswedi Anderson; Ivayla Gyurova; Lilliam Ambroggio; Sikhulile Moyo; Teresa Sebunya; Joseph Makhema; Richard Marlink; Max Essex; Rosemary Musonda; Simani Gaseitsiwe; Jason T Blackard
Journal:  Open Forum Infect Dis       Date:  2017-09-13       Impact factor: 3.835

Review 4.  Role of Kupffer Cells in Driving Hepatic Inflammation and Fibrosis in HIV Infection.

Authors:  Lumin Zhang; Meena B Bansal
Journal:  Front Immunol       Date:  2020-06-16       Impact factor: 7.561

5.  Combination antiretroviral therapy is associated with reduction in liver fibrosis scores in patients with HIV and HBV co-infection.

Authors:  Rongrong Yang; Xien Gui; Hengning Ke; Yong Xiong; Shicheng Gao
Journal:  AIDS Res Ther       Date:  2021-12-19       Impact factor: 2.250

6.  Prognostic Value of the Fibrosis-4 Index in Human Immunodeficiency Virus Type-1 Infected Patients Initiating Antiretroviral Therapy with or without Hepatitis C Virus.

Authors:  Cristina Mussini; Patrizia Lorenzini; Massimo Puoti; Miriam Lichtner; Giuseppe Lapadula; Simona Di Giambenedetto; Andrea Antinori; Giordano Madeddu; Alessandro Cozzi-Lepri; Antonella d'Arminio Monforte; Andrea De Luca
Journal:  PLoS One       Date:  2015-12-07       Impact factor: 3.240

7.  Liver Fibrosis in HIV Patients Receiving a Modern cART: Which Factors Play a Role?

Authors:  Raphael Mohr; Robert Schierwagen; Carolynne Schwarze-Zander; Christoph Boesecke; Jan-Christian Wasmuth; Jonel Trebicka; Jürgen Kurt Rockstroh
Journal:  Medicine (Baltimore)       Date:  2015-12       Impact factor: 1.817

Review 8.  Microbiota-Meditated Immunity Abnormalities Facilitate Hepatitis B Virus Co-Infection in People Living With HIV: A Review.

Authors:  Jing Ouyang; Silvere D Zaongo; Xue Zhang; Miaomiao Qi; Aizhen Hu; Hao Wu; Yaokai Chen
Journal:  Front Immunol       Date:  2022-01-06       Impact factor: 7.561

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.